+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 4829825
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pulmonary Drugs Market grew from USD 79.35 billion in 2023 to USD 86.14 billion in 2024. It is expected to continue growing at a CAGR of 8.03%, reaching USD 136.27 billion by 2030.

Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.

Regional Insights

The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Pulmonary Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
  • Improvements in reimbursements and favorable government approvals for pulmonary drugs

Market Restraints

  • Increasing recall of drugs used for pulmonary conditions

Market Opportunities

  • Development of new biologics and targeted drugs for pulmonary disease treatment
  • Advancements in inhaled drug delivery therapies and technologies

Market Challenges

  • Limitations associated with improper drug delivery and development of drug resistance

Market Segmentation Analysis

  • Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
  • Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
  • Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
  • Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
  • End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pulmonary Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics, announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of their Phase 2a trial (NCT05483907). This trial aims to evaluate the efficacy, safety, and tolerability of BBT-877 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). These promising results indicate the company’s BBT-877 has the potential to be an effective treatment for IPF when administered at the appropriate dose and schedule.

Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis

Bristol Myers Squibb has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for its potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, BMS-986278. This breakthrough therapy is intended for the treatment of progressive pulmonary fibrosis (PPF). BMS-986278 was well tolerated, with adverse event rates similar to placebo and low discontinuation rates. The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of medicines for serious or life-threatening diseases.

Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates

Aiolos Bio secured USD 245 million in Series A funding from prominent investors including Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners, Sofinnova Investments, and RA Capital Management. The funding was allocated towards Phase 2 clinical trials for Aiolos Bio's lead drug candidate, AIO-001 as a treatment for moderate-to-severe asthma patients.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pulmonary Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class

  • Anti-Cholinergic Agents
  • Anti-Leukotrienes
  • Antihistamines
  • Beta-2 Agonists
  • Combination Drugs
  • Monoclonal Antibodies
  • Oral & Inhaled Corticosteroids

Indication

  • Allergic Rhinitis
  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension

Drug Type

  • Generic Drugs
  • Prescription Drugs

Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

End-User

  • Homecare
  • Hospitals
  • Specialty Clinics

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
5.1.2. Restraints
5.1.2.1. Increasing recall of drugs used for pulmonary conditions
5.1.3. Opportunities
5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
5.1.4. Challenges
5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
5.2. Market Segmentation Analysis
5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
5.3. Market Trend Analysis
5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government’s financial support for drug commercialization
5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Pulmonary Drugs Market, by Drug Class
6.1. Introduction
6.2. Anti-Cholinergic Agents
6.3. Anti-Leukotrienes
6.4. Antihistamines
6.5. Beta-2 Agonists
6.6. Combination Drugs
6.7. Monoclonal Antibodies
6.8. Oral & Inhaled Corticosteroids
7. Pulmonary Drugs Market, by Indication
7.1. Introduction
7.2. Allergic Rhinitis
7.3. Asthma
7.4. Chronic Obstructive Pulmonary Disease
7.5. Cystic Fibrosis
7.6. Pulmonary Arterial Hypertension
8. Pulmonary Drugs Market, by Drug Type
8.1. Introduction
8.2. Generic Drugs
8.3. Prescription Drugs
9. Pulmonary Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Pulmonary Drugs Market, by End-User
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Pulmonary Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Pulmonary Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Pulmonary Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
14.3.8. U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
14.3.10. US FDA Approves GSK’s Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PULMONARY DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 75. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 76. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 77. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 78. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 83. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 84. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 85. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 86. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 87. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 88. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 89. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 90. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 91. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 92. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 93. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 94. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 95. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 96. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 97. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 98. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 99. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 100. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 101. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 102. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 103. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 104. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 105. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 106. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 107. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 108. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 115. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 116. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 117. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 118. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 119. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 120. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 128. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 130. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 132. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 137. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 138. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 139. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 140. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 141. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 142. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 143. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 144. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 145. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 146. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 147. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 148. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 149. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 150. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 151. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 152. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 153. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 154. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 155. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 156. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 157. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 158. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 159. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 160. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 161. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 162. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 165. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 166. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 167. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 168. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 169. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 170. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 171. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 172. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 173. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 174. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 175. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 176. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 177. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 178. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 179. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 180. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 181. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 182. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 185. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 186. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 187. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 188. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 189. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 190. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 191. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 192. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 195. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 196. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 197. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 198. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 199. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 200. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 201. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 202. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 205. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 206. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 207. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 208. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 209. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 210. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 211. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 212. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 215. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 216. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 217. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 218. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 219. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 220. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 221. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 222. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 225. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 226. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 227. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 228. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 229. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 230. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 231. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 232. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 233. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 234. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 235. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 236. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 237. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 238. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 239. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 240. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 241. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 245. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 246. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 247. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 248. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 249. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 250. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 251. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 252. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 265. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 266. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 267. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 268. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 269. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 270. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 271. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 272. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 273. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 274. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 275. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 276. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 277. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 278. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 279. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 280. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 281. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 282. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 283. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 284. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 285. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 286. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 287. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 288. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 289. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 290. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 291. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 292. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 293. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 294. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 295. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 296. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 297. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 298. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 299. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 300. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 301. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 302. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 303. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 304. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 305. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 306. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 307. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 308. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 309. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 310. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 311. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 312. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 313. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 314. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 317. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 318. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 319. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 320. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 321. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 322. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 323. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 324. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 325. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 326. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 327. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 328. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 329. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 330. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 331. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 332. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 333. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 334. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 335. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 336. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 337. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 338. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 339. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 340. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 341. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 342. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 343. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 344. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 345. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 346. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 347. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 348. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 349. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 350. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 351. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 352. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 353. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 354. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 355. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 356. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 357. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 358. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 359. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 360. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 361. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Chiesi Farmaceutici S.p.A
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Icosavax, Inc.
  • Johnson & Johnson Services, Inc.
  • Lung Therapeutics Inc.
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Verona Pharma PLC
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Wellona Pharma

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 86.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 136.27 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal

Related Topics

Related Reports

Global Pulmonary Drug Delivery Devices Market by Product Type (Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer), Application (Asthma, COPD, Cystic Fibrosis), Distribution Channel - Forecast 2024-2030 - Product Image

Global Pulmonary Drug Delivery Devices Market by Product Type (Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer), Application (Asthma, COPD, Cystic Fibrosis), Distribution Channel - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
Pulmonary Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Pulmonary Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Global Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Forecast 2024-2030 - Product Image

Global Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From
Pulmonary Drug Delivery Systems Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Indication, Distribution Channel, End User, and Geography - Product Image

Pulmonary Drug Delivery Systems Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Indication, Distribution Channel, End User, and Geography

  • Report
  • 150 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From

About the Pulmonary Drug Market

The Pulmonary Drug market is a subset of the larger Respiratory Drug market, which includes treatments for a variety of respiratory diseases and conditions. Pulmonary Drugs are used to treat diseases and conditions of the lungs, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary hypertension. These drugs are typically inhaled, and can include bronchodilators, corticosteroids, and antibiotics. In addition, Pulmonary Drugs can also be used to treat other respiratory conditions, such as sleep apnea and snoring. The Pulmonary Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and AstraZeneca. Other companies, such as Boehringer Ingelheim, Cipla, and Sun Pharmaceuticals, also offer Pulmonary Drugs. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.